[1]
M. Scortichini, A. Ruggieri, A. Cattaneo, P. Mascagni, and P. Sciattella, “Cost-analysis from real-world REDS study on dalbavancin in inpatient treatment of acute bacterial skin and skin structure infections”, Grhta, vol. 12, no. 1, pp. 151–157, Jun. 2025.